Robert Friesen , PhD
Chief Scientific Officer
Dr. Friesen was appointed our Chief Scientific Officer in August 2021. He has more than 20 years of experience in drug discovery and development. Previously, Dr. Friesen was CSO of Kiadis Pharma and Ablynx until their acquisitions by Sanofi. Prior to Sanofi Dr. Friesen was Senior Vice President of Research at ProQR and Vice President and Head of Biologics Research within Janssen R&D, a Johnson & Johnson company. Before joining Janssen R&D, Dr. Friesen held senior R&D positions at AM-Pharma, MorphoSys and Crucell. Dr. Friesen has authored several publications in high impact scientific journals and participated in numerous invited lectures. He has also been awarded multiple patents in the field of biotechnology. Dr. Friesen earned a M.S. in Biology from the University of Utrecht, and a Ph.D. in Biochemistry, at the University of Texas Medical Branch.